CAMBRIDGE, Mass. ( TheStreet) -- Epizyme ( EPZM) shares are weak Thursday on the disclosure of updated clinical data from the company's lead blood-cancer compound EPZ-5676 contained in a research abstract for next month's American Society of Hematology (ASH) annual meeting.
The new ASH abstract notes two of 28 patients with leukemias have achieved a complete response to treatment with EPZ-5676. Another two patients reported partial responses. The complete response rate to the drug remains unchanged from earlier this year, despite treating more patients. Epizyme will presented updated results on EPZ-5676 at the ASH meeting next month.
Epizyme shares are down 16% in Thursday trading. Last week, Epizyme announced its chief medical officer left the company.
Here's how biotech investors on Twitter reacted to the Epizyme data:
@adamfeuerstein Only 2 of 28 evaluable saw CR, same two as previously reported in Jan. Not nasty, per se, but nothing to cheer about.— Hodag (@Matt_PK1) November 6, 2014
— David Sobek (@dsobek) November 6, 2014